153 related articles for article (PubMed ID: 12384447)
21. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor.
Zhao M; Kiyoi H; Yamamoto Y; Ito M; Towatari M; Omura S; Kitamura T; Ueda R; Saito H; Naoe T
Leukemia; 2000 Mar; 14(3):374-8. PubMed ID: 10720129
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
23. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
Kiyoi H; Naoe T
Int J Hematol; 2006 May; 83(4):301-8. PubMed ID: 16757428
[TBL] [Abstract][Full Text] [Related]
24. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
25. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.
Spiekermann K; Faber F; Voswinckel R; Hiddemann W
Exp Hematol; 2002 Jul; 30(7):767-73. PubMed ID: 12135675
[TBL] [Abstract][Full Text] [Related]
26. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S
Leukemia; 1996 Dec; 10(12):1911-8. PubMed ID: 8946930
[TBL] [Abstract][Full Text] [Related]
27. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
Levis M; Murphy KM; Pham R; Kim KT; Stine A; Li L; McNiece I; Smith BD; Small D
Blood; 2005 Jul; 106(2):673-80. PubMed ID: 15797998
[TBL] [Abstract][Full Text] [Related]
28. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
[TBL] [Abstract][Full Text] [Related]
30. Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
Clark JJ; Cools J; Curley DP; Yu JC; Lokker NA; Giese NA; Gilliland DG
Blood; 2004 Nov; 104(9):2867-72. PubMed ID: 15256420
[TBL] [Abstract][Full Text] [Related]
31. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
[TBL] [Abstract][Full Text] [Related]
32. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
[TBL] [Abstract][Full Text] [Related]
33. Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Voutsadakis IA
Med Oncol; 2003; 20(4):311-24. PubMed ID: 14716027
[TBL] [Abstract][Full Text] [Related]
34. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
35. FLT3 in human hematologic malignancies.
Kiyoi H; Naoe T
Leuk Lymphoma; 2002 Aug; 43(8):1541-7. PubMed ID: 12400596
[TBL] [Abstract][Full Text] [Related]
36. Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.
Bianchini M; Ottaviani E; Grafone T; Giannini B; Soverini S; Terragna C; Amabile M; Piccaluga PP; Malagola M; Rondoni M; Bosi C; Baccarani M; Martinelli G
Clin Chem; 2003 Oct; 49(10):1642-50. PubMed ID: 14500589
[TBL] [Abstract][Full Text] [Related]
37. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract][Full Text] [Related]
38. FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
Kajiguchi T; Chung EJ; Lee S; Stine A; Kiyoi H; Naoe T; Levis MJ; Neckers L; Trepel JB
Leukemia; 2007 Dec; 21(12):2476-84. PubMed ID: 17851558
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples.
Shih LY; Huang CF; Wu JH; Wang PN; Lin TL; Dunn P; Chou MC; Kuo MC; Tang CC
Clin Cancer Res; 2004 Feb; 10(4):1326-32. PubMed ID: 14977832
[TBL] [Abstract][Full Text] [Related]
40. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
Brown P; Levis M; Shurtleff S; Campana D; Downing J; Small D
Blood; 2005 Jan; 105(2):812-20. PubMed ID: 15374878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
